Swiss National Bank Cuts Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Swiss National Bank trimmed its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 9.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 90,700 shares of the company’s stock after selling 9,900 shares during the period. Swiss National Bank owned 0.16% of Protagonist Therapeutics worth $2,080,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. lifted its stake in Protagonist Therapeutics by 353.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,675 shares of the company’s stock worth $153,000 after purchasing an additional 5,202 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Protagonist Therapeutics by 11.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,338 shares of the company’s stock valued at $237,000 after buying an additional 1,093 shares during the period. Teacher Retirement System of Texas lifted its position in shares of Protagonist Therapeutics by 6.1% in the 3rd quarter. Teacher Retirement System of Texas now owns 12,954 shares of the company’s stock worth $216,000 after purchasing an additional 740 shares during the period. Obermeyer Wood Investment Counsel Lllp boosted its position in Protagonist Therapeutics by 9.4% during the 3rd quarter. Obermeyer Wood Investment Counsel Lllp now owns 13,792 shares of the company’s stock valued at $230,000 after acquiring an additional 1,180 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in Protagonist Therapeutics by 7.7% in the third quarter. Principal Financial Group Inc. now owns 14,971 shares of the company’s stock worth $250,000 after purchasing an additional 1,068 shares in the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Price Performance

Shares of PTGX stock opened at $30.41 on Friday. The stock’s 50 day simple moving average is $27.89 and its two-hundred day simple moving average is $25.13. Protagonist Therapeutics, Inc. has a 1 year low of $13.72 and a 1 year high of $33.34. The company has a market cap of $1.78 billion, a PE ratio of 12.46 and a beta of 2.09.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Tuesday, February 27th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.39. The business had revenue of $60.00 million for the quarter, compared to the consensus estimate of $60.00 million. Equities research analysts expect that Protagonist Therapeutics, Inc. will post 1.67 EPS for the current year.

Insider Buying and Selling at Protagonist Therapeutics

In other news, CEO Dinesh V. Ph D. Patel sold 30,000 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $31.62, for a total value of $948,600.00. Following the completion of the sale, the chief executive officer now owns 574,590 shares in the company, valued at approximately $18,168,535.80. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 30,000 shares of Protagonist Therapeutics stock in a transaction on Friday, March 1st. The shares were sold at an average price of $31.62, for a total value of $948,600.00. Following the transaction, the chief executive officer now directly owns 574,590 shares of the company’s stock, valued at $18,168,535.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director William D. Waddill sold 12,975 shares of Protagonist Therapeutics stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $31.34, for a total transaction of $406,636.50. Following the completion of the sale, the director now owns 12,000 shares of the company’s stock, valued at $376,080. The disclosure for this sale can be found here. Insiders sold a total of 83,457 shares of company stock valued at $2,553,328 in the last ninety days. Corporate insiders own 5.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on PTGX. JPMorgan Chase & Co. raised their price objective on shares of Protagonist Therapeutics from $34.00 to $37.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. JMP Securities lifted their target price on Protagonist Therapeutics from $42.00 to $45.00 and gave the company a “market outperform” rating in a research report on Wednesday, May 8th. StockNews.com upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $38.00 price objective on shares of Protagonist Therapeutics in a report on Thursday, May 9th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, Protagonist Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.